Sandoz AG

Sandoz’s Canadian operation has inked a fresh ten-year supply agreement with French CDMO Delpharm Industrie, in a pact designed to secure a reliable supply of sterile injectables made in Canada. The d

Sandoz management has set out more details of how it intends to reposition in the US market the Cimerli (ranibizumab-eqrn) biosimilar to Lucentis that it licenses from Formycon. In mid-February, Germa

Reacting to a recently-filed lawsuit from Johnson & Johnson that is seeking to stop partners Samsung Bioepis and Sandoz from introducing a private-label ustekinumab biosimilar rival to Stelara in

Sandoz racked up more than $10bn in sales in 2024, with a huge boost from its biosimilars business helping to push the firm’s total turnover up by 7% to $10.36bn. “Growth was driven by strong performa